Association Between GalectiN-3 and POSt-operative AtrIal Fibrillation After Coronary Artery BypaSs Graft
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Galectin-3 dosage.
- Who it may be relevant to
- Registry conditions: Post-operative Atrial Fibrillation, Cardiovascular Diseases, Post-pericardiotomy Syndrome. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Brazil
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Association Between Galectin-3 and Post-operative AtrIal Fibrillation After Coronary Artery Bypass Graft
Overview
The goal of this observational study is to test the association between high levels of Galectin-3 and the occurrence of post-operative atrial fibrillation after isolated coronary artery bypass grafting (CABG). The main question\[s\] it aims to answer are: * Is Galectin-3 an accurate biomarker to predict higher risk of developing post-operative atrial fibrillation? * Are high levels of Galectin-3 associated to other post-operative complications and major adverse cardiovascular events? Participants will be enrolled during pre-operative evaluation and a peripheral blood sample collection will be performed in the 24h before CABG. Participants will then be followed for a period of 12 months (daily during hospitalization and 3 appointments after hospital discharge) to determine whether patients with higher levels of Galectin-3 will have worse outcomes.
Detailed description
Prospective, observational, single-center cohort study including patients undergoing coronary artery bypass graft (CABG) surgery.
Patients will be enrolled during preoperative evaluation. A peripheral blood sample will be collected within 24 hours before surgery and patients will be followed during hospitalization and for 12 months after discharge.
Interventions
- Diagnostic test Galectin-3 dosage
Peripheral blood sample will be collected in the 24h before CABG
Primary outcome measures
- Galectin-3 and post-operative atrial fibrillation [Time frame: Up to 7 days after surgery]
Secondary outcome measures (3)
- Galectin-3 and other post-operative complications [Time frame: 6 weeks]
- Galectin-3 and major adverse cardiovascular events [Time frame: 12 months]
- Galectin-3 and left atrial remodeling [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Patients undergoing coronary artery bypass graft surgery
Exclusion criteria
- Inability to sign the free and informed consent form
- Renal dysfunction with estimated glomerular filtration rate less than 30ml / min / 1.73m² or dialysis therapy
- Moderate to severe left ventricular dysfunction (ejection fraction < 40%)
- Patients with previous atrial fibrillation
- Pregnancy
- Concomitant valve surgery
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Brazil · 1 center
- Instituto do Coração - Hospital das Clínicas - Faculdade de Medicina da Universidade de Sã — São Paulo
Identifiers
NCT: NCT06768528 · SDC 5346/21/121